Skip to main content

Table 1 Clinico-pathological characteristics of the patients (n = 8703)

From: Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes

Characteristics Number of patients,
or median (range)
Percentage of the study population
Age, years
 median (range) 53.7 (21.8–90.9) NA
Size of tumor
 T1 4042 46
 T2 3416 39
 T3–T4 1074 12
 missing data 171 2
Nodal status
 N0 4593 53
 N1 3052 35
 N2 575 7
 N3 219 3
 missing data 264 3
SBR grade
 I 689 8
 II 4034 46
 III 3730 43
 missing data 250 3
Inflammatory breast cancer
 yes 317 4
 no 8201 94
 missing data 185 2
Laterality
 right 4197 48
 left 4347 50
 bilateral 76 1
 missing data 83 1
Estrogen receptor status
 negative 2468 28
 positive 6191 71
 missing data 44 0.5
Progesterone receptor status
 negative 3717 43
 positive 4908 56
 missing data 78 1
HER2 status
 negative 5504 63
 positive 3199 37
Breast cancer subtypes
 triple-negative breast cancer 1115 13
 luminal breast cancer 4355 50
 HER2-positive breast cancer 3199 37
 missing data 34 0.4
Outcomes
 recurrences 1025 12
 deaths 423 5
- related to breast cancer 359 4
- unrelated to breast cancer 64 0.7
  1. SBR Scarff-Bloom-Richardson, HER2 human epidermal growth factor receptor 2, NA not applicable